;
Home | Accelerate@Babraham | Portfolio Start-Ups

Portfolio Start-Ups

Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community. As part of this initiative StartUP@Babraham is a competition specifically to support ideas and/or companies that are pre-seed to seed stage (below £500k investment). Each year, via a rigorous application and selection process, a handful of early stage life sciences enterprises are selected to take part in this bio-entrepreneurial programme. In addition to a place on the programme, ventures also receive a non-diluted cash award , free lab and office space and proactive introductions to the campus’ global network, including mentoring and business support.

The ventures listed below have successfully completed the bio-entrepreneurial programme to date.

ANTIVERSE LTD

Accelerated drug discovery. 1 day return instead of the industry standard of 3-18 months. Antiverse uses superior scale, consistent quality and target binding.

www.antiverse.io

CCBio

CCBio are harnessing the power of synthetic biology to develop exquisitely specific antimicrobials for the treatment of urogenital/vaginal pathogens, transforming the treatment of infections which affect millions of women worldwide.

www.ccbio.co.uk

ENHANC3DGenomics

ENHANC3DGenomics is developing a platform technology that enables linking genomic variants in non-coding genomic regions to their target genes.

KALIUM HEALTH

Developing the world’s first blood potassium test for home and bedside use. It has the potential to improve the lives of over 2 million people.

MicrofluidX

MicrofluidX develops a closed, fully scalable automated bioprocessing platform, based on microfluidics, targeted at large-scale advanced therapy manufacturing, in partnership with the Cell and Gene Therapy Catapult and Centre for Process Innovation.

www.microfluidx.co.uk

OPPILOTECH LTD

Oppilotech are building one of the most detailed computational network models of the outer envelope of Gram-negative bacteria that has ever been assembled.

www.oppilotech.com

QKINE LTD

Qkine manufacturers high quality growth factors and cytokines. The company has a strong foundation of know-how and plans to develop this portfolio.

qkine.com

Reflection Therapeutics

Reflection Therapeutics is creating a first in class treatment for motor neurone disease. We will protect motor neurons from an overactive immune system, prolonging their function and delaying disease progression.

www.reflectiontherapeutics.com

Shift Bioscience

Shift Bioscience is a pre-clinical drug discovery and development company extending healthy lifespan by targeting root causes of aging.

shiftbioscience.com

TropoFour Therapeutics

TropoFour Therapeutics develops small molecules that change the activity of Tropomyosin4. They change the number of blood platelets and are novel drugs for diseases like Essential Thrombocythaemia and Cardiovascular disease.

VISUSNANO LTD

VisusNano have developed drug-releasing lens implants for use in cataract surgery, providing sustained, controlled release of drugs within the eye.

www.visusnano.com

View More

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;